Tuebingen, Germany, February 11, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced the ...
A risky but often lifesaving surgery that removes damaged parts of the small intestine can leave patients facing a new threat ...
Automatic Classification of Tumor Response From Radiology Reports With Rule-Based Natural Language Processing Integrated Into the Clinical Oncology Workflow Pending validation in larger studies, ctDNA ...
Seventy-six patients with LL-mCRC were retrospectively included. DNA from tumor tissue was sequenced, and one somatic mutation was then assessed by digital droplet polymerase chain reaction in plasma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results